GlassScriptPhysician profile
Traci Taylor Gray
NPI 1831759547
$3,397.29
in general payments reported to CMS, 2019-2025
27 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.95 · 2023: $550 · 2024: $1,295 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,169 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.35 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $770.84 | 2023-2025 | |
| Axsome Therapeutics, INC. | $652.68 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $495.44 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $200.42 | 2024-2025 | Spravato |
| Indivior INC. | $172.98 | 2021-2025 | Sublocade |
| Lilly USA, LLC | $138.97 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Braeburn INC. | $137.76 | 2023-2025 | Brixadi |
| Pfizer INC. | $134.64 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.46 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $74.82 | 2023-2025 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $65.71 | 2025 | Rexulti |
| Abbott Laboratories | $60.97 | 2023-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $52.88 | 2024 | |
| Ardelyx, INC. | $52.29 | 2025 | Ibsrela |
| Organon LLC | $51.67 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.95 | 2023-2024 | Wegovy |
| Tris Pharma INC | $29.89 | 2025 | Dyanavel Xr |
| Verrica Pharmaceuticals INC. | $24.78 | 2023 | Ycanth |
| Insulet Corporation | $23.47 | 2025 | Omnipod |
| Ironshore Pharmaceuticals INC. | $20.60 | 2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $20.48 | 2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.45 | 2023 | Xifaxan |
| Biogen, INC. | $16.61 | 2024 | Skyclarys |
| Biohaven Pharmaceuticals, INC. | $14.71 | 2021 | |
| Athena Bioscience, LLC | $14.09 | 2023 | Nexiclon Xr |
| Xeris Pharmaceuticals, INC. | $13.87 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $13.86 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.